Genomictree Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Sung-Whan An

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	15.5%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	Veri yok

Son yönetim güncellemeleri

Güncelleme yok

Recent updates

What You Need To Know About Genomictree Inc.'s (KOSDAQ:228760) Investor Composition

Feb 11

CEO

Sung-Whan An (63 yo)

no data

Görev süresi

Dr. Sungwhan An, Ph D., serves as Chief Executive Officer and President of Genomictree, Inc. Dr. An was a postdoctoral fellow in the Standford University School of Medicine from 1999 to 2000. He earned his...

Genomictree Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Recent updates

New major risk - Financial data availability

Full year 2023 earnings released: ₩391 loss per share (vs ₩316 loss in FY 2022)

New major risk - Share price stability

New major risk - Revenue and earnings growth

New major risk - Share price stability

New major risk - Share price stability

Genomictree Inc. announced that it has received KRW 5.00000105 billion in funding from ORION Holdings Corp.

Genomictree Inc. (KOSDAQ:A228760) agreed to acquire 4.8% stake in optoLANE Technologies Inc for KRW 5 billion.

Genomictree Inc. announced that it has received KRW 59.9999768 billion in funding from a group of investors

Genomictree Inc. announced that it expects to receive KRW 59.9999768 billion in funding from a group of investors

Full year 2020 earnings released: ₩590 loss per share (vs ₩533 loss in FY 2019)

New 90-day low: ₩12,150

What You Need To Know About Genomictree Inc.'s (KOSDAQ:228760) Investor Composition

New 90-day low: ₩13,750

New 90-day low: ₩13,900

New 90-day low: ₩16,250

New 90-day high: ₩19,300

CEO

Görev süresi